Pancreatic fat content by magnetic resonance imaging in subjects with prediabetes, diabetes, and controls from a general population without cardiovascular disease

Sophia D. Heber, Holger Hetterich, Roberto Lorbeer, Christian Bayerl, Jürgen Machann, Sigrid Auweter, Corinna Storz, Christopher L. Schlett, Konstantin Nikolaou, Maximilian Reiser, Annette Peters, Fabian Bamberg

1 Department of Diagnostic and Interventional Radiology, University of Tuebingen, Tuebingen, Germany, 2 Institute of Clinical Radiology, Ludwig-Maximilian-University Hospital, Munich, Germany, 3 Section on Experimental Radiology, Department of Diagnostic and Interventional Radiology, University Hospital Tuebingen, Tuebingen, Germany, 4 Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tuebingen, Germany, 5 German Center for Diabetes Research (DZD), Tuebingen, Germany, 6 Department of Radiology, Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany, 7 German Center for Cardiovascular Disease Research (DZHK e.V.), Munich, Germany, 8 Institute for Cardiovascular Prevention, Ludwig-Maximilian-University-Hospital, Munich, Germany, 9 Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

*Fabian.bamberg@uni-tuebingen.de

Abstract

Background/Objective
Despite the relevance of pancreatic fat content in the development of metabolic diseases, its association with impaired glucose metabolism, diabetes, and other adipose tissue compartments remains unclear. Thus, we determined differences in pancreatic fat content by magnetic resonance imaging (MRI) between subjects with prediabetes, diabetes, and normal controls in a cohort from the general population.

Methods
Subjects without history of cardiovascular disease with established diabetes or prediabetes as well as normal controls were included and underwent whole-body MRI on a 3T scanner. Pancreatic fat content was quantified by measuring the proton-density fat fraction (PDFF_parc) using a 3D multi-echo GRE sequence (increment: 1.23 ms, 6 echoes) by placing ROIs in the pancreatic head, body, and tail by independent readers. In addition, hepatic fat content as well as abdominal subcutaneous and visceral adipose tissue (SAT and VAT) were measured by multi-echo GRE and 3D 2-point volume-interpolated DIXON MRI, respectively. Univariate and multivariate analyses were employed to determine associations.

Results
A total of 385 subjects were included in the analysis (median age: 57 years, 58.2% males), of them 53 were classified as subjects with diabetes, 95 as prediabetes, and 237 as controls.
(13.8%, 24.7%, and 61.6%; respectively). The median PDFF\textsubscript{panc} was 5.2% [IQR 3.3–9.4], and significantly higher in subjects with prediabetes and diabetes as compared to controls (PDFF\textsubscript{panc}: 6.2% [IQR: 3.5–12] vs. 8.6% [IQR: 4.3–17.5] vs. 4.9% [3.1–7.4], p<0.001, respectively). After adjusting for age, gender and BMI the association was attenuated (all p>0.12). While in univariate analysis BMI, PDFF\textsubscript{hepatic}, SAT and VAT were associated with PDFF\textsubscript{panc} (all p<0.05), only VAT predicted PDFF\textsubscript{panc} independently (β: 0.02, 95%-confidence interval: 0.01–0.04, p<0.001).

**Conclusion**
While pancreatic fat content differs significantly between subjects with prediabetes, diabetes and controls, this association may be confounded by age, gender, and the amount of VAT in this cross-sectional study.

**Introduction**
While it is well established that diabetes mellitus is associated with increased cardiovascular morbidity and mortality [1, 2], higher risk of hospitalization [3], and a substantial healthcare burden [4], there is a large group of subjects not yet classifying as diabetic but already presenting with impaired glucose metabolism [5]. This group of subjects with prediabetes exhibits not only increased rates of progression to diabetes mellitus but also carries a significant risk of cardiovascular disease and may therefore may represent a valuable prevention target [6]. While obesity plays a central role in the disease process, there is increasing evidence that local fat depots, such as abdominal visceral adipose tissue (VAT) rather than general adiposity can be linked with impaired glucose metabolism [7, 8]. However, the specific role of the different fat depots in the development of prediabetes and diabetes is still not fully understood.

This is particularly relevant for the accumulation of ectopic fat in the pancreas, also known as fatty pancreas [9]. Pancreatic fat content may play a role in several local pathological processes such as pancreatic cancer or subtypes of pancreatitis [10, 11]. In addition, available data suggest that decreased pancreatic volume and increased pancreatic fat content are more frequently observed in subjects suffering from impaired glucose metabolism [12, 13] and pancreatic fat content was reported to correlate with insulin secretion in subjects at increased risk for metabolic diseases [14]. Larger studies covering greater numbers of participants report rather inconsistent results on a direct association of pancreatic fat content and impaired glucose metabolism [15, 16]. One explanation of these heterogeneous findings may be the different imaging modalities used for the assessment of pancreatic fat content, including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) [15–20]. Given its non-ionizing nature and high soft tissue contrast, MRI may be particularly suited to gain insights into the role of pancreatic fat content [17].

Thus, the objective of this study was to determine differences in pancreatic fat content as measured by MRI between subjects with prediabetes, diabetes, and normal controls in a cohort from the general population. In addition, findings were compared with other fat depots, including hepatic fat content, subcutaneous, and visceral adipose tissue. Our hypothesis was, there are differences in pancreatic fat content between subjects with prediabetes, diabetes, and healthy controls.
Methods

Study design

The “Cooperative Health Research in the Region of Augsburg” (KORA) study was designed as a nested, prospective case-control study in the southern part of Germany [21]. Among subjects enrolled in the KORA-FF4 cohort, eligible subjects with prediabetes, diabetes, and controls underwent whole-body MRI. The study was approved by the local institutional review board of the Ludwig-Maximilian-University Munich and informed written consent was obtained from all participants. The detailed study protocol as well as the inclusion and exclusion criteria are described elsewhere [22]. Briefly, subjects without contraindications to MRI and without history of prior cardiovascular disease (such as prior percutaneous coronary intervention, myocardial infarction or bypass graft, peripheral artery disease, or stroke), who were classified as either diabetic, prediabetic, or normal controls were eligible. The imaging protocol included MR sequences for characterization of the cardiovascular and metabolic system. All subjects also underwent a comprehensive assessment for the presence of cardiovascular risk factors at the study center.

Covariates

All covariates were obtained from actual measurements during the study visit. For classifying subjects into the three subgroups, an oral glucose tolerance test was performed for all subjects not yet being diagnosed with diabetes. Diabetes was defined as fasting glucose ≥7.0 mmol/l (126 mg/dl) and/or 2–h serum glucose ≥11.1 mmol/l (200 mg/dl) according to WHO recommendations [23]. Similarly, prediabetes was defined as either impaired glucose tolerance (IGT) with a normal fasting glucose and a 2-hour glucose between >7.8 and <11.1 mmol/l (140 mg/dl and 200 mg/dl) and/or an impaired fasting glucose (IFG) with a fasting glucose 6.1–6.9 mmol/l (110 mg/dl–125 mg/dl) and a 2-hour glucose <7.8 mmol/l (140 mg/dl). Normal controls were classified by the absence of either diabetes or prediabetes (2-hour serum glucose under 140 mg/dl and fasting glucose under 110 mg/dl) [23]. Relevant cardiovascular risk factors were collected as part of the KORA study protocol [21]. In brief, BMI was calculated as weight (kg) divided by height squared (m²). Hypertension was defined as a systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg or the intake of antihypertensive medication. Alcohol consumption was classified according to the anamnesis of drinking no alcohol at all (0 g/day), moderate alcohol consumption (0.1–39.9 g/day for men and 0.1–19.9 g/day for women) and heavy alcohol consumption (≥40 g/day for men and ≥20 g/day for women) [24]. Smoking status was defined as never-, ex- and current smoker. Medication being antihypertensive by most recent guidelines was defined as ‘antihypertensive medication’ and lipid-lowering medication was defined as the routinely intake of statins, fibrates or other lipid lowering agents.

MR imaging protocol

Whole-body MRI examinations were performed on a 3 Tesla Magnetom Skyra MRI (Siemens Healthcare, Erlangen, Germany). All subjects underwent an identical imaging protocol on the same MR scanner. The complete imaging protocol including technical details is provided elsewhere [22]. As part of the imaging protocol, a 3D multi-echo Dixon sequence [25] of the upper abdomen was employed for the assessment of pancreatic and hepatic fat content which included the following parameters: time-to-repetition (TR) 8.90 ms, time-to-echo (TE) 1.23 ms (opposed-phase), TE2 2.46 ms (in-phase), TE3 3.69 ms (opposed-phase), TE4 4.92 ms (in-phase), TE5 6.15 ms (opposed-phase), TE6 7.38 ms (in-phase), flip angle 4°, partition thickness...
4mm, field-of-view (FOV) read 420mm, and FOV phase 78.1%. Acquisitions were obtained during a breath-hold of approximately 15 seconds. These measurements account for confounders such as T2* decay, T1 bias, noise bias and fat composition [26], resulting in the relative proton density fat fraction (PDFF). An automated calculation and output of a stack with quantitative coding of PDFF in degrees of gray values was performed and archived to the PACS-system.

For quantification of SAT, and VAT parameters, a two point Dixon gradient-echo (GRE) sequence was employed with the following parameters: TR 4.06 ms, TE 1.26, 2.49 ms, flip angle 9˚, partition thickness 1.7 mm, isotropic in-plane resolution 1.7 mm. These measurements also account for hemosiderin deposition using R2* within a single breath-hold.

**MR image analysis**

Image analysis was performed on a dedicated off-line workstation by readers unaware of the diabetes status or any other information pertaining to the risk status of the subjects.

**Pancreatic fat content.** For quantitative assessment of pancreatic fat content (measured as proton-density fat fraction [PDFF\textsubscript{panc}]), circular regions of interest (ROI) covering an area of approximately 100 mm\textsuperscript{2} were drawn into the pancreatic head (caput), the pancreatic body (corpus) and the pancreatic tail (cauda) in different MRI-slices (Fig 1) using a dedicated off-line workstation (Syngo Via, Siemens Healthcare, Erlangen, Germany) [19, 27]. Images with severe image artifacts (e.g. phase swaps) were excluded from the analysis. The data were recorded in a database. Inter-reader and intra-reader variability was assessed in a subset of 40 subjects. Intra- and interobserver variability was low (ICC: 0.95 95%-CI 0.90 to 0.97 and ICC: 0.80, 95%-CI: 0.66 to 0.89; respectively). The reliability of PDFF measurements has previously been validated [15].

**Hepatic fat content.** Based on the acquired multi-echo Dixon images of the upper abdomen, hepatic fat content measured as PDFF\textsubscript{hepatic} was derived from a single axial slice at the level of the portal vein. As such, a ROI was drawn into the liver parenchyma, carefully avoiding inclusion of visible extra- and intrahepatic vessels, and absolute PDFF\textsubscript{hepatic} was calculated. Again, images with significant artifacts were excluded from the analysis [28].

**SAT and VAT.** Abdominal adipose tissue compartments were estimated from a single axial slice at the umbilical level, as it has been shown that measurements in this slice are representative for the total amount of VAT location [29]. This slice was reconstructed from the 3D

![Fig 1. Assessment of pancreatic fat content in subjects with lower and higher pancreatic fat content undergoing 3T magnetic resonance imaging (multi-echo GRE Dixon sequence) from the general population. Pancreatic fat content was measured as proton-density fat fraction (PDFF\textsubscript{panc}) in a region of interest (red circle). L = liver; S = spleen.](https://doi.org/10.1371/journal.pone.0177154.g001)
VIBE-Dixon images which were assessed in coronal direction. Axial slices were reconstructed with a slice thickness of 5mm. SAT and VAT were segmented applying an automated procedure based on fuzzy-clustering [30].

Statistical analysis

Descriptive characteristics of the study group are presented as median (25th and 75th percentile [interquartile range, IQR]) or absolute numbers (percent values). Differences between healthy controls, participants with prediabetes and diabetes were assessed by Kruskal-Wallis equality-of-populations rank test (quantitative data) or $\chi^2$ test (qualitative data). Differences of outcome parameters of pancreatic fat content among diabetic status groups were additionally assessed by test for trend and displayed by box-and-whisker plots. Agreements of pancreatic fat content parameters of the caput, corpus and cauda within the groups were investigated by Friedman’s analysis of variance test. Correlations of pancreatic fat content with VAT, SAT, PDFF$_{hepatic}$ and BMI were demonstrated by scatter plots and Spearman’s rho correlation coefficients were provided.

Effects of prediabetes and diabetes status as well as other cardiovascular risk factors for skewed distributed pancreatic fat content were estimated median with 95% confidence intervals (CI) from quantile regression in unadjusted models. Associations between diabetic status and pancreatic fat content were further adjusted for age, sex and BMI using multivariable quantile regression.

A two-sided p-value of $<0.05$ was considered to indicate statistical significance. Statistical analyses were performed using Stata 14.1 (Stata Corporation, College Station, TX, U.S.A.).

Results

Of 400 enrolled subjects, 385 subjects were included in the present analysis with complete image acquisition and sufficient image quality (96.25%); they were predominantly middle aged men (median age: 57 [IQR: 48–64] years; 58.2% males). Among them, 53 were classified as diabetic, 95 as prediabetic, and 237 as controls (13.8%, 24.7%, and 61.6%; respectively). Detailed demographics are provided in Table 1. Subjects with diabetes were generally older, more likely male, and had a higher BMI, whereas control subjects were youngest, more likely female, and with lowest BMI (all $p<0.05$). Subjects with prediabetes ranged in between controls and subjects with diabetes with respect to cardiometabolic risk profiles.

Prediabetic and diabetic subjects had a significantly higher amount of PDFF$_{hepatic}$, VAT, and SAT compared to healthy controls and were more often under lipid-lowering and anti-hypertensive medication. There was no difference of lifestyle factors, such as alcohol consumption and smoking between the groups.

Pancreatic fat content by MRI

The median of average PDFF$_{panc}$ in all subjects was 5.2% [IQR: 3.3–9.4] and there was no significant difference with respect to measurements obtained in the caput, corpus or cauda (Fig 2; all $p>0.05$). PDFF$_{panc}$ was significantly higher in the prediabetic (PDFF$_{panc}$ 6.2% [IQR: 3.5–12]) and highest in the diabetic (PDFF$_{panc}$ 8.6% [IQR: 4.3–17.5]) subjects in comparison with healthy controls (p-value for trend: $<0.001$). These differences for prediabetes and diabetes were also observed in groupwise comparison ($p=0.045$ and $p<0.001$ for prediabetes and diabetes as compared to controls, respectively). After adjusting for age, gender and BMI, the observed differences for PDFF$_{panc}$ between subjects with prediabetes, diabetes, and controls were attenuated ($\beta$: -0.43, 95%-CI: -1.84–0.98 and $\beta$: 1.4, 95%-CI -0.38–3.18 for prediabetes and diabetes, respectively).
Predictors of pancreatic fat content

In univariate analysis, the majority of established cardiometabolic risk factors, including age, male gender, hypertension and triglyceride levels were significantly and positively associated with PDFF<sub>panc</sub> (Table 2). Moreover, BMI, SAT, VAT, and PDFF<sub>hepatic</sub> correlated significantly with PDFF<sub>panc</sub> (Fig 3), while total cholesterol, LDL-concentration, and lifestyle factors such as current smoking, moderate and heavy alcohol consumption were not significantly associated.
In contrast, higher levels of HDL, the intake of lipid-lowering medication as well as anti-hypertensive medication was associated with lower amounts of PDFF\textsubscript{panc}. After adjusting for SAT, VAT and PDFF\textsubscript{hepatic}, as well as other potential confounders, only VAT remained a significant predictor of PDFF\textsubscript{panc} ($\beta$: 0.02, 95%-CI 0.01–0.04), whereas particularly the associations for PDFF\textsubscript{hepatic}, SAT and BMI became non-significant (Table 3).

### Discussion

In this cohort from the general population, our results demonstrate that there are differences in pancreatic fat content between subjects with prediabetes, diabetes, and normal controls, with a continuous increase in PDFF\textsubscript{panc} from controls, to prediabetes, to subjects with established diabetes. However, our results also indicate that these associations are not independent of other established risk factors, predominantly age, gender and BMI. Moreover, when taking into account other ectopic fat compartments, the effect on pancreatic fat content may be predominantly confounded by visceral adipose tissue. Thus, our results emphasize the role of visceral adipose tissue in the development of a hyperglycemic metabolism.

It is well established that ectopic fat compartments play a central role in the development of metabolic disease states [31]. Major interest has been raised to pancreatic fat content, given its

### Table 2. Univariate analysis of associations between demographic and cardiometabolic risk factors and pancreatic fat content. $\beta$-coefficients derived from median regression, CI, confidence interval. PDFF: proton-density fat fraction.

| Predictor                             | Estimate (Beta) | 95%-CI       | P-value |
|---------------------------------------|-----------------|--------------|---------|
| Age (years)                           | 0.13            | 0.07–0.18    | <0.001  |
| Male gender                           | 1.20            | 0.14–2.26    | 0.03    |
| BMI                                   | 0.39            | 0.28–0.49    | <0.001  |
| Diabetes Status                       |                 |              |         |
|   • Control                           | Reference       |              |         |
|   • Prediabetics                      | 1.30            | 0.03–2.57    | 0.045   |
|   • Diabetics                         | 3.63            | 2.05–5.22    | <0.001  |
| Hypertension                          | 2.03            | 0.76–3.30    | 0.002   |
| Systolic blood pressure (mmHg)        | 0.06            | 0.03–0.09    | <0.001  |
| Diastolic blood pressure (mmHg)       | 0.07            | 0.02–0.12    | 0.003   |
| Triglyceride levels (mg/dl)           | 0.02            | 0.01–0.02    | <0.001  |
| Total cholesterol (mg/dl)             | 0.01            | -0.01–0.02   | 0.39    |
| HDL (mg/dl)                           | -0.04           | -0.06–0.01   | 0.006   |
| LDL (mg/dl)                           | 0.01            | 0.03         | 0.08    |
| PDFF\textsubscript{hepatic} (%)       | 0.2             | 0.14–0.27    | <0.001  |
| VAT (cm$^2$)                          | 0.03            | 0.02–0.04    | <0.001  |
| SAT (cm$^2$)                          | 0.01            | 0.01–0.02    | <0.001  |
| Lipid lowering medication             | -2.1            | -3.69–0.51   | 0.01    |
| Anti-hypertensive medication          | -1.77           | -3.11–0.43   | 0.01    |
| Smoking status                        |                 |              |         |
|   • Never-Smoker                      | Reference       |              |         |
|   • Ex-Smoker                         | 1.3             | 0.17–2.43    | 0.02    |
|   • Current-Smoker                    | -0.07           | -1.47–1.34   | 0.93    |
| Alcohol consume (g/day)               |                 |              |         |
|   • No                                | Reference       |              |         |
|   • Moderate                           | -0.23           | -1.42–0.95   | 0.70    |
|   • Heavy                             | 0.1             | -1.3–1.5     | 0.89    |
focal accumulation in the insulin-producing organ and presumably effect on endocrine function [14]. However, while early research was hampered by limited assessment of the pancreas by reliable techniques, recent research has been fostered by the implementation of advanced imaging modalities [12, 19, 27]. Previous research on pancreatic fat content has suggested that it is increased in hyperglycemic metabolic states [13] but also that there may be less differences than initially anticipated [15]. In a sample from the general population including subjects with prediabetes, diabetes, and normal controls, we now provide more detailed knowledge on that specific topic.

Table 3. Multivariate associations between demographics, cardiometabolic risk factors and pancreatic fat content.

| Predictor                        | Average PDFF<sub>panc</sub>(%) | β (95% CI) | P-value |
|----------------------------------|---------------------------------|------------|---------|
| Age (years)                      |                                 | 0.03 (-0.04; 0.10) | 0.419   |
| Male gender                      |                                 | -0.05 (-1.49; 1.38) | 0.942   |
| BMI                              |                                 | 0.09 (-0.18; 0.36)  | 0.513   |
| Diabetes Status                  |                                 |            |         |
| • Control Reference              |                                 | Reference   |         |
| • Prediabetics                   |                                 | -0.80 (-2.29; 0.69) | 0.290   |
| • Diabetics                      |                                 | -0.27 (-2.36; 1.83) | 0.803   |
| Hypertension                     |                                 | 0.69 (-0.67; 2.04)  | 0.318   |
| Triglyceride levels (mg/dl)      |                                 | 0.00 (-0.01; 0.01)  | 0.938   |
| HDL (mg/dl)                      |                                 | 0.01 (-0.03; 0.05)  | 0.682   |
| LDL (mg/dl)                      |                                 | 0.01 (-0.01; 0.02)  | 0.571   |
| PDFF<sub>hepatic</sub> (%)       |                                 | -0.01 (-0.10; 0.08) | 0.882   |
| VAT (cm<sup>2</sup>)             |                                 | 0.02 (0.01; 0.04)   | <0.001  |
| SAT (cm<sup>2</sup>)             |                                 | 0.00 (-0.01; 0.01)  | 0.812   |
| Lipid lowering medication        |                                 | 0.15 (-1.89; 2.19)  | 0.885   |
| Smoking status                   |                                 |            |         |
| • Never-Smoker                   |                                 | Reference   |         |
| • Ex-Smoker                      |                                 | 0.5 (-0.75; 1.75)   | 0.432   |
| • Current-Smoker                 |                                 | -0.25 (-1.83; 1.32) | 0.750   |

https://doi.org/10.1371/journal.pone.0177154.t003
Our results show that a median of average PDFF\textsubscript{panc} of 5.2% can be assumed across all groups. This finding is in line with Kuhn et al., who found a mean unadjusted PDFF of 4.4% in subjects from the SHIP-study in Northern Germany [15]. Also, similar values (average pancreas PDFF 5.7%) were reported by Idilman et al. in 41 subjects with biopsy-proven non-alcoholic fatty liver disease (NAFLD) [17]. While we confirm these prior observations, our results also demonstrate that there is a continuous increase in PDFF\textsubscript{panc} ranging from healthy controls to subjects with prediabetes to diabetes. Similar observations have also been made by Dong et al. [12] who describe an increase in pancreatic fat content in subjects with impaired glucose metabolism as assessed by MRI in 83 subjects.

However, after adjustment for age and gender, these differences between controls and subjects with prediabetes were attenuated. While it is well known that pancreatic fat content is higher in elderly people and in men [9, 15, 32], differences were maintained for subjects with diabetes, potentially indicating the more advanced stage of disease with detectable morphological changes [13]. When additionally adjusting for BMI, the observed differences for pancreatic fat content in diabetic subjects were also attenuated. As such, our findings are in line with Kuhn et al., who did not find a relation of pancreatic fat content to impaired glucose metabolism [15]. Indirect confirmation stems from a recent longitudinal study showing that pancreatic fat content was not associated with the development of diabetes in a 5-year cohort study [33]. Moreover, a lack of association between pancreatic fat content and impaired beta-cell function has been reported earlier [34, 35].

In the present study, we now provide more detailed insights into the independent associations of pancreatic fat content and other ectopic fat compartments as measured by MRI. Specifically, we found VAT, SAT, and PDFF\textsubscript{hepatic} were higher in subjects with prediabetes and diabetes. Our observed differences of ectopic fat compartments between subjects with prediabetes, diabetes, and controls are in line with previous research. For instance, Neeland et al. found that in 732 obese subjects from the Dallas Heart study excess visceral fat was associated with incident prediabetes and type 2 diabetes [7].

Notably, we found that among the three examined adipose compartments, VAT remained the only independent predictor of pancreatic fat content. The association between VAT and pancreatic fat content has been described earlier [14, 32, 36]. For instance, Rossi et al. found that VAT by MRI was the strongest predictor for pancreatic fat content in a study comprising 12 lean and 38 obese subjects [32]. We now confirm this finding in a significantly larger cohort. VAT has recently been identified as a major risk factor for metabolic disease states and cardiovascular disease [37, 38] and our study contributes to the acknowledgement of the central role of VAT in the development of metabolic disease states.

With VAT being the only independent predictor of PDFF\textsubscript{panc} in multivariate analysis, it is striking that the existing associations of other potential factors, including PDFF\textsubscript{hepatic} and BMI were attenuated in multivariate analysis. Again, this finding may highlight the central role of VAT in the pathogenesis of metabolic disease states [38]. Clearly, our results confirm the inferior role of BMI as compared with a more detailed imaging-based assessment of body composition (including VAT) as a crude estimate of body composition [39].

As the predominant effect of VAT in hypermetabolic states is substantial, at least from a clinical point of view, it may be subject to discussion whether clinical implementation of assessment of VAT may be beneficial in a selected set of subjects at increased risk for metabolic diseases in order to develop beneficial health care programs [40]. First studies presenting automated assessment of MRI-derived fat depots resulted in promising findings [30]. However, further evidence and dedicated cost-effectiveness analyses are certainly needed.

Interestingly, we did not detect any independent association between lipid-lowering medication and PDFF\textsubscript{panc} beyond VAT whereas lipid lowering medication had a protective effect
in univariate analysis. In a 10 year follow up study it has been shown that lipid lowering medication was not associated with a risk to develop type 2 diabetes mellitus [41]. Similar observations concerning the non-existence of an independent association were made by us with respect to smoking status, potentially indicating the inert role of pancreatic fat content to this external factor. However, smoking is a risk factor for pancreatic cancer [42]. A beneficial effect of subgroups of antihypertensive medication, such as valsartan (angiotensin type 1 receptor blocker), in the metabolic syndrome has been suggested [43], nevertheless we mainly focused on the more obvious interactors of pancreatic fat content such as BMI, VAT, SAT and PDFFhepatic.

Our study has some limitations. First, the analysis cohort represents a sample from a healthy population in Germany, thus generalizability to other, particularly non-European populations may be limited. Our groups of individuals were not matched adequately in order to compensate for differences beyond the presence of pancreatic fat content (i.e. age and gender). However, differences were accounted for using multivariate analysis adjusting for all differences detected in univariate analysis. Despite that we applied multivariate adjustment in our analysis, it needs to be highlighted that this approach may induce collinearity (i.e. between pancreatic fat and VAT) and a true increase in pancreatic fat may be falsely attenuated by VAT. Thus, further confirmatory, more homogeneously matched group comparisons are warranted. Notably, not all subjects were firstly diagnosed as prediabetes and diabetes and the majority of subjects were under medication according to current guidelines. However, as such the study cohort represents a very representative sample from a western European population and we have adjusted for these differences using multivariate analysis. In addition, we did not define a cut-off value for the definition of pancreatic steatosis but employed the average PDFF pancreas values. While this may be in contrast to other approaches, it provides more pathophysiological insights into the disease process. While we applied an established method of measuring pancreatic fat content by PDFF [15, 17, 19], it may be that visceral adipose tissue may have contaminated these measurements. However, while our approach is in line with previous research and measurements carefully avoided the inclusion of adjacent visceral fat, further more detailed assessment of pancreatic tissue compartments is warranted. We also assessed pancreatic fat content manually, which may limit the opportunity to apply the approach to larger cohorts and samples. However, more advanced post-processing techniques are currently being developed, which may overcome the need for manual segmentation in the near future [30].

In conclusion, our results indicate that PDFF pancreas is significantly higher in subjects with prediabetes and diabetes as compared to healthy controls. However, this association may be confounded by age, gender, and the amount of VAT in this cross-sectional study.

Author Contributions

Conceptualization: FB AP MR KN.

Data curation: FB HH SA KN.

Formal analysis: RL SDH.

Funding acquisition: FB AP MR HH.

Investigation: HH CB JM.

Methodology: HH JM SDH CLS CS FB.

Project administration: FB AP.
Resources: SA RL.
Supervision: FB MR.
Visualization: RL CLS CS SDH.
Writing – original draft: SDH FB CLS CS.
Writing – review & editing: SDH HH RL CB JM SA CLS CS KN MR AP FB.

References
1. Sarwar N, Gao P, Seshasai SR, Grong R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (London, England). 2010; 375(9733):2215–22. Epub 2010/07/09.
2. Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr., Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009; 119(13):1728–35. Epub 2009/03/25. https://doi.org/10.1161/CIRCULATIONAHA.108.829176 PMID: 19307472
3. Schneider AL, Kalyani RR, Golden S, Stearns SC, Wruck L, Yeh HC, et al. Diabetes and Prediabetes and Risk of Hospitalization: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes care. 2016; 39(5):772–9. Epub 2016/03/10. https://doi.org/10.2337/dc15-1335 PMID: 26953170
4. Dall TM, Yang W, Halder P, Pang B, Massoudi M, Wintfeld N, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes care. 2014; 37(12):3172–9. Epub 2014/11/22. https://doi.org/10.2337/dc14-1036 PMID: 25414388
5. James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, et al. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes care. 2011; 34(2):387–91. Epub 2011/01/29. https://doi.org/10.2337/dc10-1314 PMID: 21270196
6. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet (London, England). 2006; 368(9548):1651–9. Epub 2006/11/14.
7. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. Jama. 2012; 308(11):1150–9. Epub 2012/09/20. https://doi.org/10.1001/jama.2012.1132 PMID: 22990274
8. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. The Journal of clinical investigation. 2015; 125(5):1790–2. Epub 2015/05/02. https://doi.org/10.1172/JCI81507 PMID: 25932676
9. Lesmana CR, Pakasi LS, Inggrani S, Aidawati ML, Lesmana LA. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC gastroenterology. 2015; 15:174. Epub 2015/12/15. https://doi.org/10.1186/s12876-015-0404-1 PMID: 26652175
10. Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R, et al. Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. Journal of the American College of Surgeons. 2009; 208(5):989–94; discussion 94–6. Epub 2009/05/30. https://doi.org/10.1016/j.jamcollsurg.2008.12.026 PMID: 19476877
11. Pitt HA. Hepato-pancreato-biliary fat: the good, the bad and the ugly. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2007; 9(2):92–7. Epub 2008/03/12.
12. Dong Z, Luo Y, Cai H, Zhang Z, Peng Z, Jiang M, et al. Noninvasive fat quantification of the liver and pancreas may provide pivotal biomarkers of impaired glucose tolerance and type 2 diabetes. Medicine. 2016; 95(23):e3858. Epub 2016/06/10. https://doi.org/10.1097/MD.0000000000003858 PMID: 27281097
13. Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R. Altered volume, morphology and composition of the pancreas in type 2 diabetes. PloS one. 2015; 10(5):e0126825. Epub 2015/05/08. https://doi.org/10.1371/journal.pone.0126825 PMID: 25950180
14. Heni M, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes/metabolism research and reviews. 2010; 26 (3):200–5. Epub 2010/03/13. https://doi.org/10.1002/dmrr.1073 PMID: 20225188
15. Kuhn JP, Berthold F, Mayerle J, Volzke H, Reeder SB, Rathmann W, et al. Pancreatic Steatosis Demonstrated at MR Imaging in the General Population: Clinical Relevance. Radiology. 2015; 276(1):129–36. Epub 2015/02/07. https://doi.org/10.1148/radiol.15140446 PMID: 25658037
32. Rossi AP, Fantin F, Zamboni GA, Mazzali G, Rinaldi CA, Del Giglio M, et al. Predictors of ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with diabetes. PLoS ONE. 2013; 8(5):e62561. Epub 2013/05/15. https://doi.org/10.1371/journal.pone.0062561 PMID: 23671610

33. Idilman IS, Tuzun A, Savas B, Elhan AH, Celik A, Idilman R, et al. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease. Abdominal imaging. 2015; 40(6):1512–9. Epub 2015/02/27. https://doi.org/10.1007/s00261-015-0385-0 PMID: 25715922

34. Kim SY, Kim H, Cho JY, Lim S, Cha K, Lee KH, et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology. 2014; 271(1):104–12. Epub 2014/01/31. https://doi.org/10.1148/radiol.13122883 PMID: 24475851

35. Patel NS, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2013; 37(6):630–9. Epub 2013/02/07.

36. Sepe PS, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett G, et al. A prospective evaluation of fatty pancreas by using EUS. Gastrointestinal endoscopy. 2011; 73(5):987–93. Epub 2011/04/28. https://doi.org/10.1016/j.gie.2011.01.015 PMID: 21521567

37. Holle R, Happich M, Lowel H, Wichmann HE, Group MKS. KORA—a research platform for population based health research. Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)). 2005; 67 Suppl 1:S19–25.

38. Bamberg F, Hetterich H, Rospeszczas L, Lorbeer R, Auweter SD, Schlett CL, et al. Subclinical Disease in Subjects with Prediabetes, Diabetes and Normal Controls from the General Population: the KORA MRI-Study. Diabetes. 2016.

39. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization, 2006.

40. Rul E, Baumert J, Meisinger C, Doring A, Ladwig KH. Are psychosocial stressors associated with the relationship of alcohol consumption and all-cause mortality? BMC public health. 2014; 14:312. Epub 2014/04/09. https://doi.org/10.1186/1471-2458-14-312 PMID: 24708657

41. Bashir MR, Zhong X, Nickel MD, Fananapazir G, Kammengiesser SA, Kiefer B, et al. Quantification of hepatic steatosis with a multistep adaptive fitting MRI approach: prospective validation against MR spectroscopy. AJR American journal of roentgenology. 2015; 204(2):297–306. Epub 2015/01/24. https://doi.org/10.2214/AJR.13.12288 PMID: 25615751

42. Reeder SB, Sirlin CB. Quantification of liver fat with magnetic resonance imaging. Magnetic resonance imaging clinics of North America. 2010; 18(3):337–57, ix. Epub 2010/11/26. https://doi.org/10.1016/j.mric.2010.08.013 PMID: 21094444

43. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, et al. Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterology research and practice. 2013; 2013:498296. Epub 2013/12/19. https://doi.org/10.1155/2013/498296 PMID: 24348536

44. Hetterich H, Bayerl C, Peters A, Heier M, Linkohr B, Meisinger C, et al. Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population. Eur Radiol. 2015. Epub 2015/09/06.

45. Schwenzfer NF, Machann J, Schraml C, Springer F, Ludescher B, Stefan N, et al. Quantitative analysis of adipose tissue in single transverse slices for estimation of volumes of relevant fat tissue compartments: a study in a large cohort of subjects at risk for type 2 diabetes by MRI with comparison to anthropometric data. Investigative radiology. 2010; 45(12):788–94. Epub 2010/09/11. https://doi.org/10.1097/RLI.0b013e3181f10fe1 PMID: 20829704

46. Wurslin C, Machann J, Rempp H, Claussen C, Yang B, Schick F. Topography mapping of whole body adipose tissue using A fully automated and standardized procedure. Journal of magnetic resonance imaging. JMRI. 2010; 31(2):430–9. Epub 2010/01/26. https://doi.org/10.1002/jmri.22036 PMID: 20099357

47. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSJM cardiovascular disease. 2016; 5:2048004016633371. Epub 2016/03/22. https://doi.org/10.1177/2048004016633371 PMID: 26998259

48. Rossi AP, Fantin F, Zamboni GA, Mazzali G, Rinaldi CA, Del Giglio M, et al. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. Obesity (Silver Spring, Md). 2011; 19(9):1747–54. Epub 2011/05/20.

49. Yamazaki H, Tsuboya T, Katamura A, Kodama Y, Tauchi S, Dohke M, et al. Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes Mellitus: 5-Year Japanese Cohort Study. Diabetes care. 2016. Epub 2016/07/17.

50. van der Zijl NJ, Goossens GH, Moors CC, van Raalte DH, Muskiet MH, Pouwels PJ, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with diabetes. JRSM cardiovascular disease. 2016; 5:2048004016633371. Epub 2016/03/22. https://doi.org/10.1177/2048004016633371 PMID: 26998259
impaired glucose metabolism. The Journal of clinical endocrinology and metabolism. 2011; 96(2):459–67. Epub 2010/11/19. https://doi.org/10.1210/jc.2010-1722 PMID: 21084401

35. Begovatz P, Koliaki C, Weber K, Strasser R, Nowotny B, Nowotny P, et al. Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans. Diabetologia. 2015; 58(7):1646–55. Epub 2015/03/06. https://doi.org/10.1007/s00125-015-3544-5 PMID: 25740696

36. Wong VW, Wong GL, Yeung DK, Ahrig JD, Kong AP, Chan RS, et al. Fatty pancreas, insulin resistance, and beta-cell function: a population study using fat-water magnetic resonance imaging. The American journal of gastroenterology. 2014; 109(4):589–97. Epub 2014/02/05. https://doi.org/10.1038/ajg.2014.1 PMID: 24492753

37. Mathieu P, Boulanger MC, Despres JP. Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk. Reviews in endocrine & metabolic disorders. 2014; 15(4):289–98. Epub 2014/10/20.

38. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116(1):39–48. Epub 2007/06/20. PMID: 17576866

39. Camhi SM, Bray GA, Bouchard C, Greenway FL, Johnson WD, Newton RL, et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring, Md). 2011; 19(2):402–8. Epub 2010/10/16.

40. Rossi AP, Fantin F, Zamboni GA, Mazzali G, Zoico E, Bambace C, et al. Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects. Nutrition & diabetes. 2012; 2:e32. Epub 2012/01/01.

41. Hwang YC, Hayashi T, Fujimoto WY, Kahn SE, Leonetti DL, McNeely MJ, et al. Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans. Diabetes care. 2015; 38(11):2100–5. Epub 2015/09/19. https://doi.org/10.2337/dc15-0625 PMID: 26384391

42. Andersson G, Wennersten C, Borquist S, Jirstrom K. Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmo Diet and Cancer Study. Biology of sex differences. 2016; 7:66. Epub 2016/12/17. https://doi.org/10.1186/s13293-016-0120-8 PMID: 27960714

43. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension (Dallas, Tex: 1979). 2010; 55(3):715–21. Epub 2010/01/27.